glp-1 treatment for newly diagnosed diabetes guidelines 2026 Update: ADA vs NICE What Is a GLP-1 Journey:

Rapid weakness, severe fatigue, confusion, or inability to eat enough

The FDA has acknowledged this reality on the label itself: weight care requires ongoing therapy , and GLP-1 drugs are approved for chronic weight management only as an adjunct to diet and exercise they are not magic bullets that cure obesity after a few doses

The results from the Boston collaborators raised questions about the physiological way that GLP-1 prompted the release of insulin, a phenomenon described as an 'insulinotropic effect' (Drucker, Philippe, Mojsov)

This review outlines the rationale for their development and summarizes clinical trial data, focusing on retatrutide, the most advanced candidate